



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
Express Mail Label No. EY2040589871US

Express Mail Label No. EV204058987US

Approved for use through 10/31/2002, OMB 0651-0931

TRADEMARK OFFICE, U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number

information unless it displays a valid CMB control number.

Express Mail Label No. EV204058987US

0/520768

3/320/68

1/10/2005

ban F.

624

Balasubraman

AB 1301 USWQ

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

<u>Application Number</u>	10/520768
<u>Filing Date</u>	01/10/2005
<u>First Named Inventor</u>	Jean F. Lacrampe
<u>Group Art Unit</u>	1624
<u>Examiner Name</u>	V. Balasubramanian
<u>Attorney Docket Number</u>	JAB 1701USWO

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature	V. Balasubramanian	Date Considered	10/1/06
--------------------	--------------------	-----------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached *Kinds of U.S. Patent Documents*. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

<i>Application Number</i>	10/520768
<i>Filing Date</i>	01/10/2005
<i>First Named Inventor</i>	Jean F. Lacrampe
<i>Group Art Unit</i>	1624
<i>Examiner Name</i>	V. Balasubramanian
<i>Attorney Docket Number</i>	JAB 1701USWO

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
VB		ABRAHAM et al., "Cellular Effects of Olomoucine, An Inhibitor of Cyclin-Dependent Kinases.", <i>Biol. Cell.</i> 1995, pages 105-120, Vol. 83.	
IM		DELIA, Thomas, "Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotiazines.", <i>Heterocyclic Compounds</i> , John Wiley & Sons, Inc., Interscience Publications, pages 281-304.	
IM		GENNARO et al. <i>Remington's Pharmaceutical Sciences</i> , 19 <sup>th</sup> ed., Mack Publishing Company, 1990, see especially Part 8 : Pharmaceutical preparations and their Manufacture.	
W		GREENE et al., "Protective Groups in Organic Synthesis", 2 <sup>nd</sup> edition, Wiley Interscience, 1991.	
W		KAUR et al., "Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275.", <i>Journal of the National Cancer Institute</i> , Nov. 18, 1992, pages 1736-1740, Vol. 84, No.22.	
W		MEDER, Laurent, "Chemical Inhibitors of Cyclin-Dependent Kinases.", <i>Progress in Cell Cycle Research</i> , 1995, pages 351-363, Vol.1.	
W		NAGAMATSU et al., "Syntheses of 3-Substituted 1-Methyl-6-Phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones (6-Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.", <i>Chem Pharm Bull.</i> 1993, pages 362-368, Vol. 41, No. 2.	
W		NAGAMATSU et al., "Facile And General Syntheses of 1-Alkytoxoflavins and 8-Alkyfervenulin Derivatives of Biological Significance By The Regiospecific Alkylation of Reumycin (1-Demethyltoxoflavin, 8-Demethylfervenulin) Derivatives.", <i>Heterocycles</i> , 1997, pages 643-650, Vol. 45, No. 4.	
W		NAGAMATSU et al., "General Syntheses of 1-Alkytoxoflavin and 8-Alkyfervenulin Derivatives of Biological Significance By The Regioslective Aylation of Reumycin Derivatives And The Rates of Transalkylation From 1-Alkytoxoflavins Into Nucleophiles.", <i>J. Chem. Soc. Perkin Trans. 1</i> , 2001, pages 130-137.	
W		"Protective Groups in Organic Chemistry", edited by J W F McOmie, 1973, Plenum Press.	
W		SEDLACEK et al., "Flavopiridol (L86 8275; NSC 649890), A New Kinase Inhibitor For Tumor Therapy.", <i>International Journal of Oncology</i> , 1996, pages 1143-1168, Vol. 9.	
W		SMIRNOVA et al., "Purines, Pyrimidines, And Condensed Systems Based on Them. 9. Concerning The Synthesis of 1-R-Pyrazolo[3,4-d]Pyrimidine-4,6-Diones.", 1992, pages 181-185, Plenum Publishing Corporation-Translated from Khimika Geterotsiklicheskikh Sopstvennosti, Feb. 1992, pages 219-224, No. 2.	
W		STREITWEISER, A., "Introduction to Organic Chemistry", Second Ed., Macmillan Publishing Inc., pages 1104-1105.	
W		VESELY et al., "Inhibition of Cyclin-Dependent Kinases By Purine Analogues.", <i>Eur. J. Biochem.</i> , 1994, pages 771-786, Vol. 224.	
W		YONEDA et al., "A Convenient Synthesis of Toxoflavins And Toxoflavin-N-Oxides.", <i>Tetrahedron Letters</i> , 1971, pages 851-854, Vol. 13, Pergamon Press, Great Britain.	
W		YONEDA et al., "Transformation of Toxoflavins into Fervenulin Via 1-Demethyltoxoflavins.", <i>Tetrahedron Letters</i> , 1973, pages 1577-1580, No. 17, Pergamon Press, Great Britain.	
W		YONEDA et al., "Synthesis and Properties of 6-Benzyl Analogs of Toxoflavin.", <i>Journal of Heterocyclic Chemistry</i> , 1974, pages 83-95, Vol. 11, No.1.	
W		YONEDA et al., "A New Method For The Transformation of Toxoflavins to Fervenulins.", <i>Journal of Heterocyclic Chemistry</i> , 1974, pages 271-273, Vol. 11, No. 2.	
W		YONEDA et al., "A New Synthetic Method of Toxoflavin Derivatives.", <i>Synthesis</i> , March 1975, pages 177-179, Vol. 3.	
W		YONEDA et al., "A Convenient Synthesis of Toxoflavins, Toxoflavin 4-oxides and 1-Demethyltoxoflavins.", <i>Chem. Pharm. Bull.</i> , 1975, pages 2001-2009, Vol. 23, No. 9.	
W		YONEDA et al., "New Syntheses of Fervenulin (1,3-Dimethyl-7-azatuzazine) and Analogs.", <i>Bulletin of The Chemical Society of Japan</i> , 1975, pages 2884-2887, Vol. 48, No. 10.	
W		YONEDA et al., "A New Synthesis of Pyrimido[4,5-e]-as-triazine 4-Oxides by Nitrosative Cyclization of Aldehyde Uracil-6-Vlydrazone in the Presence of Diethyl Azidomformate.", <i>Journal of the Chemical Society</i> , 1976, pages 713-715, Vol. 7.	
W		YONEDA et al., "6-Azapurines (Imidazo[4,5-e]-as-triazines).", <i>Journal of The Chemical Society. Chemical Communications</i> , 1976, pages 658-659, Vol.16.	
W		YONEDA et al., "Syntheses of Isoalloazines, Toxoflavins, and Fervenulins By Oxidative Cyclization of the Michael-type Adducts from Substituted 6-Aminouracils and Azo-Compounds.", <i>Journal of The Chemical Society. Perkin Transactions I</i> , 1976, pages 2398-2402, Vol. 22.	
IM			

Examiner Signature	V. Balasubramanian	Date Considered	10/17/06
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



SEP 15 2006

Express Mail Label No. EV204058987US

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

<u>Application Number</u>	10/520768
<u>Filing Date</u>	01/10/2005
<u>First Named Inventor</u>	Jean F. Lacrampe
<u>Group Art Unit</u>	1624
<u>Examiner Name</u>	V. Balasubramanian
<u>Attorney Docket Number</u>	JAB 1701USWO

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Signature	<u>V. Balasubramanian</u>	Date Considered	10/11/06
-----------------------	---------------------------	--------------------	----------